South Korea Ophthalmic Drugs Market Size & Outlook
The ophthalmic drugs market in South Korea is expected to reach a projected revenue of US$ 1,716.8 million by 2033. A compound annual growth rate of 10.2% is expected of South Korea ophthalmic drugs market from 2026 to 2033.
- Pharmaceuticals
- Ophthalmology Drugs
- Ophthalmic Drugs Market Outlook
- Ophthalmology Drugs
Revenue, 2025 (US$M)
$788.2
Estimate, 2026 (US$M)
$868.7
Forecast, 2033 (US$M)
$1,716.8
CAGR, 2026 - 2033
10.2%
Global Market
Related Markets
Prism AI by Grand View ResearchFree to try
Ask a question about the ophthalmic drugs market
Every figure cited from GVR research
South Korea ophthalmic drugs market highlights
- The South Korea ophthalmic drugs market generated a revenue of USD 788.2 million in 2025 and is expected to reach USD 1,716.8 million by 2033.
- The South Korea market is expected to grow at a CAGR of 10.2% from 2026 to 2033.
- In terms of segment, anti-vegf agents was the largest revenue generating drug class in 2025.
- Anti-VEGF agents is the most lucrative drug class segment registering the fastest growth during the forecast period.
Ophthalmic drugs market data book summary
| Market revenue in 2025 | USD 788.2 million |
| Market revenue in 2033 | USD 1,716.8 million |
| Growth rate | 10.2% (CAGR from 2026 to 2033) |
| Largest segment | Anti-vegf agents |
| Fastest growing segment | Anti-VEGF agents |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Anti-VEGF agents, Anti-glaucoma, Anti-inflammatory, Anti-Allergy |
| Key market players worldwide | Pfizer Inc, Alcon Inc, Novartis AG ADR, Bausch Health Companies Inc, Merck & Co Inc, Regeneron Pharmaceuticals Inc, AbbVie Inc, Bayer AG, Genentech, Nicox SA Share from reverse split, Coherus BioSciences Inc |
Other key industry trends
- In terms of revenue, South Korea accounted for 1.9% of the global ophthalmic drugs market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China ophthalmic drugs market is projected to lead the regional market in terms of revenue in 2033.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 2,495.2 million by 2033.
No credit card required*
Publish Date: Apr 16, 2026
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Ophthalmic Drugs Market Scope
Ophthalmic Drugs Market segmentation & scope
Ophthalmic Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Alcon Inc | View profile | 25,315 | Chemin de Blandonnet 8, Royce Bedward, Vernier, Geneva, Switzerland, 1214 | www.alcon.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| Bayer AG | View profile | 99,723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | www.bayer.com |
| Regeneron Pharmaceuticals Inc | View profile | 13,450 | 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 | www.regeneron.com |
| Bausch Health Companies Inc | View profile | 20,270 | 2150 Saint Elzear Boulvard West, Laval, QC, Canada, H7L 4A8 | www.bauschhealth.com |
| Genentech | View profile | 10001+ | South San Francisco, California, United States, North America | gene.com |
| Coherus BioSciences Inc | View profile | 306 | 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, United States, 94065 | www.coherus.com |
South Korea Ophthalmic Drugs Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Ophthalmic Drugs Market Outlook will help companies and investors design strategic landscapes.
Anti-Vegf Agents was the largest segment with a revenue share of 39.62% in 2025.
Horizon Databook has segmented the South Korea ophthalmic drugs market based on anti-vegf agents, anti-glaucoma, anti-inflammatory, anti-allergy covering the revenue growth of each sub-segment from 2021 to 2033.
- South Korea Ophthalmic Drugs Market Drug Class Outlook (Revenue, USD Million , 2021-2033)
- Anti-Allergy
- Anti-VEGF agents
- Anti-glaucoma
- Gene & Cell Therapy
- Others
- Anti-inflammatory
- South Korea Ophthalmic Drugs Market Disease Outlook (Revenue, USD Million , 2021-2033)
- Dry Eye
- Allergies
- Glaucoma
- Infection
- Retinal Disorders
- Uveitis
- Others
- South Korea Ophthalmic Drugs Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Topical
- Systemic
- Local Ocular
- South Korea Ophthalmic Drugs Market Dosage Type Outlook (Revenue, USD Million , 2021-2033)
- Gels
- Eye solutions & suspensions
- Capsules & Tablets
- Eye drops
- Ointments
- South Korea Ophthalmic Drugs Market Product Type Outlook (Revenue, USD Million , 2021-2033)
- OTC drugs
- Prescription
- South Korea Ophthalmic Drugs Market Drug Type Outlook (Revenue, USD Million , 2021-2033)
- Branded Drugs
- Generic Drugs
Reasons to subscribe to Ophthalmic Drugs Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Ophthalmic Drugs Market Outlook databook
- Our clientele includes a mix of Ophthalmic Drugs Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea Ophthalmic Drugs Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into South Korea Ophthalmic Drugs Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
South Korea Ophthalmic Drugs Market, 2021-2033 (US$M)
South Korea ophthalmic drugs market statistics, by drug class, 2021-2033 (US$M)
